Effects of selective serotonin reuptake inhibitors on glaucoma: A nationwide population-based study.

Habitual intake of selective serotonin reuptake inhibitors (SSRIs) is tied to a high risk of having glaucoma.

​This study assessed whether patients with depression treated with antidepressants belonging to the class selective serotonin reuptake inhibitors (SSRIs) were at risk of developing glaucoma. The study population comprised of over 100,000 men and women recruited from Taiwan's National Health Insurance Research Database. 

Researchers discovered that the use of selective serotonin reuptake inhibitors correlated with increased risk of glaucoma. This study provides evidence that depressive patients treated with selective serotonin reuptake inhibitors may have a high tendency of being diagnosed with glaucoma.